The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia.
Cecilia Ysabel Arana Yi
No relevant relationships to disclose
Gautam Borthakur
No relevant relationships to disclose
Peter F. Thall
No relevant relationships to disclose
Andrew L. Coveler
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Elias Jabbour
No relevant relationships to disclose
Stefan Faderl
No relevant relationships to disclose
Deborah A. Thomas
No relevant relationships to disclose
Jorge E. Cortes
No relevant relationships to disclose
Tapan M. Kadia
No relevant relationships to disclose
Steven Mitchell Kornblau
No relevant relationships to disclose
Naval Guastad Daver
No relevant relationships to disclose
Naveen Pemmaraju
No relevant relationships to disclose
Hoang Q. Nguyen
No relevant relationships to disclose
William R. Wilson
Employment or Leadership Position - Proacta
Stock Ownership - Proacta
Teresa J. Melink
Employment or Leadership Position - Proacta
Stock Ownership - Proacta
John Gutheil
Employment or Leadership Position - Proacta
Stock Ownership - Proacta
Hagop M. Kantarjian
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
Elihu Estey
Research Funding - Proacta
Marina Konopleva
Research Funding - Proacta